Only pay if approved·Free shipping·Cancel anytime·Provider supervised·HIPAA secure

Provider-prescribed treatments. Subject to medical evaluation. Medications are dispensed by licensed U.S. pharmacies.

Back to Blog
GLP-1 / Weight Loss
📚 Informational 5/20/2026 7 min readBy EdenRx Medical Team

Semaglutide Clinical Study Results: What the Research Actually Shows

Semaglutide Clinical Study Results: What the Research Actually Shows

Ready to find out if you may qualify?

No payment required to start · Takes less than 60 seconds · Only pay if approved

Check Your Eligibility Free
No Payment Required Response Within 24h Built from Eden Med Spa

Key Takeaways

  • 1The STEP 1 trial found that eligible adults using semaglutide 2.4 mg weekly may lose an average of approximately 14.9% of body weight over 68 weeks — though individual results vary.
  • 2STEP 4 data suggests that ongoing semaglutide use may be necessary to sustain weight loss, as participants who discontinued the medication regained significant weight.
  • 3Provider review is critical for safe semaglutide use — EdenRx offers a free, provider-reviewed assessment for eligible patients in Florida and New York.

Semaglutide clinical study results have consistently shown that this GLP-1 receptor agonist may support meaningful weight loss in adults who are eligible for treatment under medical supervision. While individual results vary, the body of clinical evidence makes semaglutide one of the most studied weight loss medications available today.

Ready to find out if you qualify? Start Free Assessment — No payment required.

What Is Semaglutide and How Was It Studied?

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes management and later studied extensively for chronic weight management. To understand how semaglutide works, it helps to know that it mimics a natural hormone that regulates appetite, slows gastric emptying, and signals fullness to the brain — all of which may contribute to reduced caloric intake over time.

The landmark clinical program behind semaglutide for weight loss is called the STEP (Semaglutide Treatment Effect in People with Obesity) trials. These were large-scale, randomized, double-blind, placebo-controlled studies conducted across multiple countries, involving thousands of adult participants with a BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity. The trials were designed to evaluate the safety and efficacy of once-weekly subcutaneous semaglutide at doses up to 2.4 mg.

STEP 1: The Foundational Weight Loss Trial

The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults without type 2 diabetes. Participants were randomized to receive either 2.4 mg of semaglutide weekly or a placebo, alongside lifestyle intervention counseling. After 68 weeks, those in the semaglutide group experienced an average body weight reduction of approximately 14.9%, compared to 2.4% in the placebo group. Results vary between individuals, but these findings were statistically significant and clinically meaningful.

Importantly, a greater proportion of participants in the semaglutide group achieved weight loss thresholds of 5%, 10%, and 15% or more of their body weight compared to placebo. These findings suggest that semaglutide may potentially offer a tiered benefit — meaning many eligible patients could see moderate results, while a subset may experience more substantial reductions. If you are exploring options in Florida, our semaglutide Florida program is provider-reviewed and tailored to your health profile.

STEP 2: Findings in Adults With Type 2 Diabetes

The STEP 2 trial focused specifically on adults living with type 2 diabetes, a population where weight management can be particularly challenging. This trial enrolled 1,210 participants and compared semaglutide 2.4 mg, semaglutide 1.0 mg, and placebo over 68 weeks. The 2.4 mg group achieved an average weight reduction of approximately 9.6%, compared to 3.4% in the placebo group — a statistically significant difference that also came with improvements in glycemic markers.

This trial is especially relevant because it underscores that semaglutide may potentially benefit individuals managing both obesity and metabolic conditions simultaneously. As always, eligibility and appropriate dosing should be determined by a licensed provider who reviews your full medical history. EdenRx's programs are designed with exactly this personalized, provider-first approach in mind.

STEP 3, STEP 4, and Sustained Results

STEP 3 examined semaglutide alongside intensive behavioral therapy, finding that the combination may yield even greater outcomes than either intervention alone — approximately 16% mean weight reduction in the semaglutide group versus 5.7% with placebo. STEP 4 took a unique "withdrawal" design: participants who had already lost weight on semaglutide were randomized to either continue or switch to placebo. Those who continued semaglutide maintained their weight loss, while the placebo group regained an average of 6.9% of their body weight. This suggests that ongoing treatment may be necessary to sustain results.

These findings align with what we understand about obesity as a chronic condition requiring long-term management strategies. If you have been wondering about semaglutide vs tirzepatide, the STEP trial data provides an important baseline for comparing GLP-1 class medications — each with its own clinical profile, dosing schedule, and suitability depending on patient history.

Safety Profile and Reported Side Effects

Across the STEP trials, the most commonly reported side effects of semaglutide were gastrointestinal in nature, including nausea, vomiting, diarrhea, and constipation. These effects were generally mild to moderate in severity, most often occurred during the dose-escalation phase, and tended to decrease over time. Discontinuation rates due to adverse events were higher in the semaglutide group than placebo but remained relatively low overall.

Serious adverse events were uncommon and were thoroughly evaluated in all trial arms. As with any prescription medication, individual tolerance and contraindications must be assessed on a case-by-case basis. This is why provider review is a foundational element of any responsible semaglutide program — and why EdenRx requires a full clinical assessment before any treatment is considered. You can review transparent pricing information on our site so there are no surprises.

Why Provider Review Matters

The clinical studies on semaglutide were conducted under strict medical supervision with ongoing monitoring, dose titration protocols, and regular safety check-ins. Real-world outcomes depend heavily on whether patients receive appropriate screening, dosing guidance, and follow-up care — factors that are often absent in unregulated or "online only" sources. Using semaglutide without a proper provider review may expose patients to unnecessary risks, including contraindicated use in those with certain thyroid conditions, pancreatitis history, or specific medication interactions.

At EdenRx, every patient inquiry goes through a provider-reviewed assessment process. Our clinical team evaluates your health history, goals, and eligibility before any treatment recommendation is made. Built from Eden Med Spa — real patients, real treatments. We are currently serving eligible patients in Florida and New York, and our protocols are designed to reflect the same standards seen in major clinical research programs.


Think semaglutide may be right for you? Start your free assessment today and let our provider team review your eligibility — no payment required to get started. See our pricing page for full plan details.


Frequently Asked Questions

What do semaglutide clinical study results show about average weight loss? In the STEP 1 trial, participants using 2.4 mg semaglutide weekly lost an average of approximately 14.9% of their body weight over 68 weeks. Results vary between individuals, and outcomes depend on adherence, lifestyle factors, and medical eligibility.

Is semaglutide FDA-approved for weight loss? Yes, semaglutide 2.4 mg (brand name Wegovy) is FDA-approved for chronic weight management in adults with a BMI of 30 or greater, or 27 or greater with at least one weight-related condition, such as high blood pressure or type 2 diabetes.

How long does it take to see results with semaglutide? Clinical trials ran for 68 weeks, and meaningful weight loss was generally observed within the first 12–20 weeks as doses were titrated upward. Individual timelines may vary, and sustained use appears necessary to maintain results based on STEP 4 findings.

What are the most common side effects seen in clinical studies? The most frequently reported side effects in the STEP trials were nausea, vomiting, diarrhea, and constipation. These were generally mild to moderate, most common during dose escalation, and often resolved over time. A provider should always review your full health history before starting.

How does semaglutide compare to other GLP-1 medications like tirzepatide? Both semaglutide and tirzepatide have clinical evidence supporting weight loss, but they work through slightly different mechanisms. Tirzepatide targets both GLP-1 and GIP receptors. See our full semaglutide vs tirzepatide comparison for a detailed breakdown to discuss with your provider.

Is EdenRx available outside of Florida and New York? Currently, EdenRx serves eligible patients in Florida and New York only. We are a provider-reviewed telehealth platform, and our clinical team ensures that all treatments are prescribed and monitored in compliance with state regulations in those jurisdictions.


Conclusion: What the Science May Mean for You

The body of semaglutide clinical research is robust, peer-reviewed, and encouraging — but it's also clear that supervised, individualized care is essential for safe and potentially effective outcomes. The STEP trials demonstrate that semaglutide may offer meaningful weight loss support for eligible adults, particularly when used consistently and under medical guidance. As with all prescription treatments, results vary and no outcome is guaranteed.

If you are in Florida or New York and are curious about whether you may be a candidate for a semaglutide program, EdenRx makes it easy to take the first step. Our provider-reviewed process starts with a free assessment and is built around your health, not a one-size-fits-all protocol.

Take the first step today. Start your free assessment at EdenRx — provider-reviewed, transparent pricing, and real clinical support for eligible patients in Florida and New York.

See if you qualify in 60 seconds

Provider-reviewed · Only pay if approved · Cancel anytime

Start Free Medical Assessment
No Payment Required Response Within 24h Built from Eden Med Spa
semaglutide GLP-1 weight loss clinical studies STEP trials telehealth Florida New York obesity treatment semaglutide clinical study results

Share This Article

Share Text

Semaglutide clinical studies show ~15% avg weight loss in eligible adults. Here's what the STEP trials really found — and how provider review makes all the difference. #Semaglutide #WeightLoss #GLP1

No payment required to start — get up to $50 off your first month.

A licensed provider reviews every case. Only pay if approved. Cancel anytime.

Start Free Medical Assessment
No Payment Required Response Within 24h Built from Eden Med Spa
Live Activity
143 people online now
1,121 visits today
10 orders shipped today
HIPAA Secure